← Krystal Biotech, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($1.1m) |
($7.9m)
-588.70%
|
($10.9m)
-37.49%
|
($19.1m)
-75.30%
|
($32.2m)
-68.52%
|
($69.6m)
-116.28%
|
($140.0m)
-101.20%
|
$10.9m
+107.81%
|
$89.2m
+715.58%
|
$204.8m
+129.74%
|
— | |
| Depreciation, Depletion and Amortization | $2k | $23k | $141k | $748k | $1.9m | $2.8m | $2.6m | $5.0m | $6.0m | $5.7m | $6.7m | |
| Depreciation | $2k | $23k | $141k | $748k | $1.5m | $1.8m | $2.6m | $5.0m | $6.0m | $5.7m | $6.7m | |
| Amortization | — | — | — | — | — | — | $1.4m | ($1.3m) | — | — | ($2.3m) | |
| Deferred Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.0m | $6.2m | ($27.3m) | ($22.8m) | |
| Share-based Payment Arrangement, Noncash Expense | $33k | $246k | $792k | $1.2m | $3.3m | $15.3m | $33.2m | $39.9m | $49.1m | $54.5m | $54.7m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | $0 | $649k | $749k | — | — | — | |
| Share-based Payment Arrangement, Expense | $33k | $246k | $792k | $1.2m | $3.3m | $13.7m | — | — | — | $54.5m | $54.7m | |
| Nonoperating Income (Expense) | ($7k) | ($3.1m) | — | — | — | — | — | — | — | — | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | $0 | $42.0m | $62.7m | $22.1m | ($27.3m) | |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | $0 | $4.5m | $11.9m | $6.3m | ($7.0m) | |
| Increase (Decrease) in Accounts Payable | $42k | $133k | $112k | ($199k) | $783k | $712k | ($1.3m) | ($101k) | $1.0m | $826k | ($124k) | |
| Net Cash Provided by (Used in) Operating Activities | ($1.3m) |
($3.9m)
-196.72%
|
($9.4m)
-142.80%
|
($18.7m)
-98.13%
|
($26.1m)
-39.38%
|
($47.9m)
-83.79%
|
($100.6m)
-109.79%
|
($88.8m)
+11.70%
|
$123.4m
+238.98%
|
$200.9m
+62.75%
|
$272.3m
+35.58%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $15k | $210k | $2.2m | $6.4m | $14.8m | $68.3m | $53.0m | $11.8m | $4.2m | $12.0m | ($14.6m) | |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | $193.7m | $271.3m | $438.1m | — | $532.2m | $597.5m | $827.8m | — | |
| Net Cash Provided by (Used in) Investing Activities | — | — | ($10.3m) | ($5.0m) | ($11.2m) | ($226.8m) | ($114.1m) | $82.6m | ($163.4m) | ($58.4m) | ($218.3m) | |
| Cash flows from financing activities: | ||||||||||||
| Proceeds from Issuance of Common Stock | $100k | $42.5m | $73.8m | $107.5m | $118.0m | $355.6m | $36.0m | $203.5m | $0 | $0 | $0 | |
| Net Cash Provided by (Used in) Financing Activities | $3.2m |
$51.8m
+1493.35%
|
$73.8m
+42.65%
|
$107.5m
+45.61%
|
$118.0m
+9.76%
|
$347.7m
+194.60%
|
$35.3m
-89.83%
|
$202.8m
+473.60%
|
$27.0m
-86.68%
|
$8.7m
-67.78%
|
$24.0m
+175.35%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | — | $80.8m | $73.0m | ($179.3m) | $196.4m | ($13.5m) | $151.4m | $431.8m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $268.3m | $341.2m | $161.9m | $358.3m | $344.9m | $496.3m | $431.8m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $0 | $0 | ($41k) | ($156k) | ($458k) | $286k | ($4.1m) | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | $7.0m | $43.8m | $32.4m | $22.7m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, Net | — | — | — | — | $0 | $0 | $0 | $0 | $5.7m | $14.8m | — | |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | — | — | — | — | ($1.2m) | — | |
| Gain (Loss) on Disposition of Intangible Assets | — | — | — | — | — | — | $0 | $100.0m | $0 | $0 | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | — | $560k | — | — | — | $0 | — | |
| Gain (Loss) on Disposition of Assets for Financial Service Operations | — | — | — | ($67k) | ($33k) | $0 | ($72k) | ($27k) | — | — | — | |
| General and Administrative Expense | $402k | $1.6m | $4.2m | $6.5m | $15.1m | $40.4m | $77.7m | $98.4m | — | — | — | |
| Operating Expenses | $1.1m | $4.8m | $11.9m | $22.1m | $33.0m | $68.3m | $145.2m | $160.4m | $224.8m | $227.8m | — | |
| Operating Lease, Expense | — | — | — | — | $756k | $1.3m | — | — | — | — | — | |
| Realized Investment Gains (Losses) | — | — | — | — | — | — | $570k | $5.1m | $6.1m | $6.0m | — |